High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097

Interest continues to build around the early application of patient selection markers to prospectively identify patients likely to show clinical benefit from cancer therapies. Hypothesis generation and clinical strategies often begin at the preclinical stage where responder and nonresponder tumor ce...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Oncol
Glavni autori: He, Wei, Luistro, Leopoldo, Carvajal, Daisy, Smith, Melissa, Nevins, Tom, Yin, Xuefeng, Cai, James, Higgins, Brian, Kolinsky, Kenneth, Rizzo, Christine, Packman, Kathryn, Heimbrook, David, Boylan, John F.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2011
Teme:
Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528291/
https://ncbi.nlm.nih.gov/pubmed/21315665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.01.001
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items